Bosentan may be an effective therapy for patients with chronic thromboembolic pulmonary hypertension

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1605, 2007-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhaled treprostinil is an effective, well-tolerated add-on therapy for patients with pulmonary arterial hypertension (PAH) treated with bosentan

By  

Inpharma, Vol. 1, Iss. 1561, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Bosentan effective in severe pulmonary hypertension

By  

Inpharma, Vol. 1, Iss. 1331, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Bosentan: In Pediatric Patients with Pulmonary Arterial Hypertension

By Carter Natalie J.   Keating Gillian M.  

Pediatric Drugs, Vol. 12, Iss. 1, 2010-02 ,pp. : 63-73

Adis International

Access to resources Recommend Favorite

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH)

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 508, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses

By Karavolias George K   Georgiadou Panagiota   Gkouziouta Angeliki   Kariofillis Panagiotis   Karabela Georgia   Tsiapras Dimitrios   Sbarouni Eftihia   Chaidaroglou Antigoni   Degiannis Dimitrios   Adamopoulos Stamatis   Voudris Vassilis  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 12, 2010-12 ,pp. : 1283-1289

Informa Healthcare

Access to resources Recommend Favorite